About
1849 bio engineers microbes for mining companies to economically extract copper, gold, and other metals from low-grade or difficult-to-process ores. Its differentiation is an ore-specific bioengineering and high-throughput screening platform that produces custom microbial solutions deployable through existing leaching infrastructure, potentially offering cleaner and lower-capital extraction than conventional methods.
Market
1849 bio competes in biomining and bioleaching technology, using engineered microbes to improve copper and gold recovery from low-grade ores and mining stockpiles. Its differentiation is the design of microbes with traits tailored to a specific ore and deployment without disrupting existing mine processes, whereas identified peers include companies using custom chemical additives to stimulate wild microbes or established bioleaching systems.
Mining companies—especially operators with low-grade copper or gold ores and existing stockpiles—that want lower-cost, more sustainable metal recovery. The likely buyers are mining and metallurgical/process teams at major mining corporations, with the company explicitly seeking partnerships with large mining companies.
At a Glance
Problem
1849 bio addresses the declining quality of copper ore and the resulting supply and economics problem. Biomining can cost roughly $1 per ton of ore versus about $7 for conventional processing, but existing bioleaching methods cannot be applied to more than 80% of copper ores. As a result, an estimated $800 billion of copper remains in waste materials and stockpiles with negative unit economics. The main use case is helping operating mines recover copper from low-grade stockpiles and difficult ores such as chalcopyrite, extending the value of existing assets without opening entirely new mines.
The problem is becoming more urgent as copper demand rises for electric vehicles, renewable energy, and data centers. 1849 bio frames its opportunity around approximately 100 million tonnes of copper stranded in ores that are currently not profitable to process, while the company’s YC profile cites a potential copper supply gap of about 20% by 2031.
Product / Service
1849 bio provides custom-engineered microorganisms for mine-specific metal extraction. Its process analyzes an ore sample’s mineral composition and microbiome, engineers naturally occurring microbes for traits that improve extraction from that ore, screens optimized strains in parallel, and deploys the resulting microbial solution through the mine’s existing leaching infrastructure. This is intended to improve recovery without disrupting current operations or requiring a wholly new extraction plant.
The initial product is focused on copper, particularly challenging ores such as chalcopyrite. 1849 bio claims recovery rates of up to 60%, compared with roughly 20% for conventional bioleaching, and positions the approach as lower-cost, lower-capital, and more environmentally friendly than conventional processing, with fewer tailings. The economic benefit is turning stockpiled or low-grade material from a liability into an additional source of saleable metal.
Market
1849 bio operates at the intersection of biomining, mining technology, synthetic biology, and climate-focused industrial biotechnology. It competes with conventional copper extraction and established bioleaching approaches, while adjacent startup competitors include Ceibo, which is developing low-grade copper extraction technology, and Endolith, which uses synthetic biology and microbes to improve recovery of copper and other critical minerals. The broader market is supported by rising demand for copper and the need to extract more metal from existing mines and waste streams.
The company was founded in 2024, joined Y Combinator’s Summer 2024 batch, and is listed as active. Its official site solicits mining partners for a pilot program, suggesting an early commercialization and validation phase rather than mature, scaled deployment. The reviewed public sources do not name a commercial mining customer or provide company-confirmed revenue. Third-party databases report approximately $2.41 million raised through December 2024, while one revenue tracker estimates $440,000 of 2025 revenue; because those financial figures are not confirmed by 1849 bio, the most defensible characterization is an early-stage, pilot-oriented company with initial funding and unverified early revenue rather than clearly pre-revenue or fully commercial.
Founders & Leadership
Funding History
Y Combinator
Recent News
Y Combinator’s biotech directory describes 1849 bio as designing microbes for low-cost metal extraction, helping miners unlock value from low-quality copper and gold ores.
FuturePlay’s portfolio profile describes 1849 Bio as developing biomining technology for efficient extraction of metals from low-grade copper and gold ores.
World Fund’s biomining industry article identifies 1849 Bio alongside Endolith as developing microbial platforms that adapt dynamically to changing heap conditions.
A Latka company profile reported estimated 2025 annual recurring revenue of $440,000 and a $1.8 million valuation for 1849 bio. These figures are third-party estimates rather than an announced financing round.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
1849 bio appears to use a business-to-business model selling customized microbial extraction solutions to mining operators, including strain engineering, ore-specific validation, and deployment through customers’ existing leaching infrastructure. Public sources do not disclose pricing or the precise mix of project fees, licensing, or usage-based revenue.